The MRCF invests exclusively in opportunities that are associated with our Member Institutes.
The MRCF is interested in opportunities covering the full spectrum of biomedical development, from proof of concept opportunities through to commercialisation-stage opportunities. The MRCF can provide as little as AU$500,000 investment or up to AU$30 million in funding, depending on the opportunity.
Each Member Institute has a representative on the Investment Review Committee (IRC). The Institute representative will present a brief overview of the investment opportunity to the IRC (Preliminary Investment Proposal-PIP).
If this initial proposal is recommended to progress, a presentation by the key researchers and full investment proposal (Investment Application Form – IAF) will be requested for the next IRC meeting.
If the IRC is supportive of the technology receiving investment, the opportunity is passed to the Brandon Capital Partners, who completes due diligence on each opportunity.
If Brandon Capital Partners is supportive of the opportunity, it recommends to the Board that the investment is made. Guidance is provided by Brandon Capital Partners for the preparation of both the initial and full investment proposals. Please see the ‘Contact Us’ page for contact information.
Whether the technology represents world class science;
What is required to demonstrate proof-of-concept or reach the next key milestones for the technology;
Market size and need within the market;
The competition and competitive edge of the technology;
The strength of the intellectual property position;
The key personnel and management; and Commercialisation path, likely exit and potential value at exit
The collaborative structure of the MRCF ensures that the interests of the Member Institutes, the Investors and the Fund Manager are closely aligned, thus providing a sustainable structure for the long-term success of the fund. Each Member Institute nominates a representative to the Investment Review Committee (IRC). Member Institutes are then integrally involved in all aspects of the funds activities, providing valuable input to the formal commercialisation process and also enabling peer review of investment proposals. This inclusive review process also facilitates increased communication and collaboration between Member Institutes.